Edward Romond

Edward Romond, University of Kentucky, Lexington
More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding trastuzumab to doxorubicin and cyclophosphamide followed by paclitaxel.
[audio:https://www.audiomedica.com/podcasting/ajo_13.8/02.edward_romond.mp3] …